A retrospective cohort study to determine systemic inflammation-related variables and clinicopathologic characteristics as predictive markers of response to nivolumab monotherapy in patients with advanced gastric cancer
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Nivolumab (Primary)
- Indications Gastric cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 06 Oct 2021 New trial record